ArticleThe Journal of pathology2014
Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
Article in The Journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- The Potential Role of Microalgal Antioxidant Molecules on the Microbiota-Gut Axis in Inflammatory Bowel Diseases.Biomolecules · 2025Review
- From Cytokines to Biomarkers: Mapping the Immunopathology of Inflammatory Bowel Disease.Cells · 2025Review
- Curcumin for inflammatory bowel disease therapy: advances in mechanisms, clinical applications, and drug delivery.Archives of pharmacal research · 2025Review
- RORγt-APCs: The New Masters of Oral Tolerance.Barrier immunity · 2025Article
- Dendritic cell immunometabolism - a potential therapeutic target for allergic diseases.International journal of medical sciences · 2025Review
- Spatial profiling of the mouse colonic immune landscape associated with colitis and sex.Communications biology · 2024Article
- Exploration and verification a 13-gene diagnostic framework for ulcerative colitis across multiple platforms via machine learning algorithms.Scientific reports · 2024Article
- CaCells · 2024Review
- Gut instinct: harnessing the power of probiotics to tame pathogenic signaling pathways in ulcerative colitis.Frontiers in medicine · 2024Review
- Animal models of inflammatory bowel disease: category and evaluation indexes.Gastroenterology report · 2024Review
- A multiscale mechanistic model of human dendritic cells forFrontiers in immunology · 2023Article
- Immunological Effects ofCells · 2022Article
- Regulatory T cells in skeletal muscle repair and regeneration: recent insights.Cell death & disease · 2022Review
- Metabolic programming in dendritic cells tailors immune responses and homeostasis.Cellular & molecular immunology · 2022Review
- Quercetin Administration Suppresses the Cytokine Storm in Myeloid and Plasmacytoid Dendritic Cells.International journal of molecular sciences · 2021Article
- Article
- Review
- The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea?Dermatology and therapy · 2020Review
- Article
- Clinical Use ofFrontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysfunction of the mucosal immune system plays an important role in inflammatory bowel disease (IBD) pathogenesis. Dendritic cells are emerging as central players based on both our increasing understanding of how genetic susceptibility impacts the mucosal immune system and the key role of dendritic cells in regulating response to gut microflora. We discuss areas of therapeutic opportunity in this evolving landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.